bluuebunny/crossref_metadata_2025_split huggingface dataset:
Treatment of Fluorouracil-Refractory Patients With Liver Metastases From Colorectal Cancer by Using Yttrium-90 Resin Microspheres Plus Concomitant Systemic Irinotecan Chemotherapy
Authors: van Hazel Guy A. , Pavlakis Nick , Goldstein David , Olver Ian N. , Tapner Michael J. , Price David , Bower Geoffrey D. , Briggs Gregory M. , Rossleigh Monica A. , Taylor D. James , George Jacob 
Published: August 2009

Purpose Liver metastases are the principal cause of death in patients with advanced colorectal cancer (CRC). Irinotecan is a chemotherapeutic agent used in the treatment of CRC and has demonstrated synergistic potential when used with radiation. Radioembolization with yttrium-90 microspheres has demonstrated increased response and survival rates when given with fluorouracil chemotherapy. This study's goal was to evaluate the maximum-tolerated dose of concomitant irinotecan and radioembolization in fluorouracil-refractory patients with CRC hepatic metastases. Patients and Methods Twenty-five irinotecan-naïve patients who had experienced relapse after previous chemotherapy were enrolled onto three dose-escalating groups. Irinotecan was administered at 50, 75, or 100 mg/m2 on days 1 and 8 of a 3-week cycle for the first two cycles, and full irinotecan doses (ie, 100 mg/m2) were administered during cycles 3 to 9. Radioembolization was administered during the first chemotherapy cycle. Results Most patients experienced acute, self-limiting abdominal pain and nausea. Mild lethargy and anorexia were common. Grades 3 to 4 events were seen in three of six patients at 50 mg/m2 (obstructive jaundice, thrombocytopenia, diarrhea), in five of 13 patients at 75 mg/m2 (neutropenia, leukopenia, thrombocytopenia, elevated alkaline phosphatase, abdominal pain, ascites, fatigue) and in four of six patients at 100 mg/m2 (diarrhea, deep vein thrombosis, constipation, leukopenia). Eleven (48%) of 23 patients had a partial response, and nine patients (39%) had stable disease. The median progression-free survival was 6.0 months; the median survival was 12.2 months. Conclusion Concomitant use of radioembolization plus irinotecan did not reach a maximum-tolerated dose. The recommended dose of irinotecan in this setting is 100 mg/m2 on days 1 and 8 of a 3-week cycle.
Phase III Randomized Study of Bendamustine Compared With Chlorambucil in Previously Untreated Patients With Chronic Lymphocytic Leukemia
Authors: Knauf Wolfgang U. , Lissichkov Toshko , Aldaoud Ali , Liberati Anna , Loscertales Javier , Herbrecht Raoul , Juliusson Gunnar , Postner Gerhard , Gercheva Liana , Goranov Stefan , Becker Martin , Fricke Hans-Joerg , Huguet Francoise , Del Giudice Ilaria , Klein Peter , Tremmel Lothar , Merkle Karlheinz , Montillo Marco 
Published: August 2009

Purpose This randomized, open-label, parallel-group, multicenter study was designed to compare the efficacy and safety of bendamustine and chlorambucil in previously untreated patients with advanced (Binet stage B or C) chronic lymphocytic leukemia (CLL). Patients and Methods Patients (≤ 75 years of age) were randomly assigned to receive bendamustine 100 mg/m2/d intravenously on days 1 to 2, or chlorambucil 0.8 mg/kg (Broca's normal weight) orally on days 1 and 15; treatment cycles were repeated every 4 weeks for a maximum of six cycles. The response to treatment was assessed according to National Cancer Institute Working Group criteria, and the final determination of response was made by a blinded independent review committee. Results A total of 319 patients were randomly assigned (162 bendamustine, 157 chlorambucil). Complete or partial responses were achieved in 110 (68%) of 162 bendamustine-treated and 48 (31%) of 157 chlorambucil-treated patients (P < .0001). More patients showed complete responses with bendamustine than with chlorambucil (31% v 2%). Median progression-free survival was 21.6 months with bendamustine and 8.3 months with chlorambucil (P < .0001). Bendamustine was also associated with an improvement in duration of remission, compared with chlorambucil (median, 21.8 v 8.0 months). Hematologic National Cancer Institute Common Toxicity Criteria grade 3 to 4 adverse events were more common with bendamustine than with chlorambucil (occurring in 40% v 19% of patients). Severe infections (grade 3 to 4) occurred in 8% of bendamustine-treated patients and 3% of chlorambucil-treated patients. Conclusion Bendamustine offers significantly greater efficacy than chlorambucil, and a manageable toxicity profile, when used as first-line therapy in patients with advanced CLL.
Efficacy and Safety of Trabectedin in Patients With Advanced or Metastatic Liposarcoma or Leiomyosarcoma After Failure of Prior Anthracyclines and Ifosfamide: Results of a Randomized Phase II Study of Two Different Schedules
Authors: Demetri George D. , Chawla Sant P. , von Mehren Margaret , Ritch Paul , Baker Laurence H. , Blay Jean Y. , Hande Kenneth R. , Keohan Mary L. , Samuels Brian L. , Schuetze Scott , Lebedinsky Claudia , Elsayed Yusri A. , Izquierdo Miguel A. , Gómez Javier , Park Youn C. , Le Cesne Axel 
Published: August 2009

Purpose To evaluate the safety and efficacy of trabectedin in a phase II, open-label, multicenter, randomized study in adult patients with unresectable/metastatic liposarcoma or leiomyosarcoma after failure of prior conventional chemotherapy including anthracyclines and ifosfamide. Patients and Methods Patients were randomly assigned to one of two trabectedin regimens (via central venous access): 1.5 mg/m2 24-hour intravenous infusion once every 3 weeks (q3 weeks 24-hour) versus 0.58 mg/m2 3-hour IV infusion every week for 3 weeks of a 4-week cycle (qwk 3-hour). Time to progression (TTP) was the primary efficacy end point, based on confirmed independent review of images. Results Two hundred seventy patients were randomly assigned; 136 (q3 weeks 24-hour) versus 134 (qwk 3-hour). Median TTP was 3.7 months versus 2.3 months (hazard ratio [HR], 0.734; 95% CI, 0.554 to 0.974; P = .0302), favoring the q3 weeks 24-hour arm. Median progression-free survival was 3.3 months versus 2.3 months (HR, 0.755; 95% CI, 0.574 to 0.992; P = .0418). Median overall survival (n = 235 events) was 13.9 months versus 11.8 months (HR, 0.843; 95% CI, 0.653 to 1.090; P = .1920). Although somewhat more neutropenia, elevations in AST/ALT, emesis, and fatigue occurred in the q3 weeks 24-hour, this regimen was reasonably well tolerated. Febrile neutropenia was rare (0.8%). No cumulative toxicities were noted. Conclusion Prior studies showed clinical benefit with trabectedin in patients with sarcomas after failure of standard chemotherapy. This trial documents superior disease control with the q3 weeks 24-hour trabectedin regimen in liposarcomas and leiomyosarcomas, although the qwk 3-hour regimen also demonstrated activity relative to historical comparisons. Trabectedin may now be considered an important new option to control advanced sarcomas in patients after failure of available standard-of-care therapies.
Mapatumumab, an Antibody Targeting TRAIL-R1, in Combination With Paclitaxel and Carboplatin in Patients With Advanced Solid Malignancies: Results of a Phase I and Pharmacokinetic Study
Authors: Leong Stephen , Cohen Roger B. , Gustafson Daniel L. , Langer Corey J. , Camidge D. Ross , Padavic Kristin , Gore Lia , Smith Margaret , Chow Laura Q. , von Mehren Margaret , O'Bryant Cindy , Hariharan Sujatha , Diab Sami , Fox Norma Lynn , Miceli Renée , Eckhardt S. Gail 
Published: August 2009

Purpose A phase I study assessed the safety, tolerability, pharmacokinetics, and preliminary antitumor effect of mapatumumab, a fully-human agonist monoclonal antibody to the tumor necrosis factor–related apoptosis-inducing ligand receptor 1 (TRAIL-R1, DR4), in combination with paclitaxel and carboplatin. Patients and Methods Patients with advanced solid malignancies received 3, 10, or 20 mg/kg of mapatumumab with standard doses of paclitaxel and carboplatin every 21 days for up to six cycles in the absence of disease progression. Additional cycles of paclitaxel and/or mapatumumab were permissible in selected cases. Results Twenty-seven patients (21 males), with a median age of 54 years, received mapatumumab in the following three cohorts: 3 mg/kg (n = 4), 10 mg/kg (n = 11), and 20 mg/kg (n = 12). The median number of cycles was four. Dose-limiting toxicities (DLTs) were grade 3 hypersensitivity reaction (n = 1) and neutropenic fever (n = 1), both at 10 mg/kg. Non-DLT treatment-related adverse events occurring in more than 10% of administered doses included alopecia, neutropenia, fatigue, nausea, anemia, thrombocytopenia, anorexia, and neuropathy. Paclitaxel and carboplatin exposures were similar in the presence or absence of mapatumumab. Plasma mapatumumab concentrations seemed similar to data from previous phase I monotherapy studies. Five patients (19%) achieved a confirmed radiologic partial response (including one pathologic complete response), and 12 patients (44%) had stable disease as their best response. Conclusion Mapatumumab is well-tolerated up to 20 mg/kg in combination with paclitaxel and carboplatin. There are no apparent pharmacokinetic interactions among the drugs. Preliminary anticancer activity demonstrated clinical benefit for the majority of these patients.
Ethanol Concentration Dependence of Photoinduced Charge Separation Reaction between Zinc Tetraphenylporphyrin and Duroquinone Studied by Laser Flash Photolysis
Authors: Yago Tomoaki , Gohdo Masao , Wakasa Masanobu 
Published: August 2009

Abstract
Ethanol concentration dependence of photoinduced charge separation between zinc tetraphenylporphyrin (ZnTPP) and duroquinone (DQ) in benzonitrile was studied by nanosecond laser flash photolysis. Acceleration of the photoinduced charge separation reaction rate by hydrogen bonding between DQ anion radical and ethanol was observed. A simple analysis in the framework of the Marcus theory indicated that the observed electron-transfer reaction rate was affected not only by the decrease of the reaction free energy but also an increase of the reorganization energy in the presence of hydrogen bonding.
Neomastoidin A, a Novel Monoacylglycerol with an Amino Acid Moiety from Macrolepiota neomastoidea
Authors: Kim Ki Hyun , Choi Sang Un , Lee Kang Ro 
Published: August 2009

Abstract
A novel monoacylglycerol with an amino acid moiety, neomastoidin A (1), was isolated from the fruiting bodies of the poisonous mushroom Macrolepiota neomastoidea. The structure of 1 was established by extensive spectroscopic analysis and further confirmed by application of a dibenzoate chirality method. Neomastoidin A (1) exhibited cytotoxicity against SK-OV-3 and SK-MEL-2 cell lines.
The use of MRI to detect occult fractures of the proximal femur
Authors: Sankey R. A. , Turner J. , Lee J. , Healy J. , Gibbons C. E. R. 
Published: August 2009

An MR scan was performed on all patients who presented to our hospital with a clinical diagnosis of a fracture of the proximal femur, but who had no abnormality on plain radiographs. This was a prospective study of 102 consecutive patients over a ten-year period. There were 98 patients who fulfilled our inclusion criteria, of whom 75 were scanned within 48 hours of admission, with an overall mean time between admission and scanning of 2.4 days (0 to 10). A total of 81 patients (83%) had abnormalities detected on MRI; 23 (23%) required operative management. The use of MRI led to the early diagnosis and treatment of occult hip pathology. We recommend that incomplete intertrochanteric fractures are managed non-operatively with protected weight-bearing. The study illustrates the high incidence of fractures which are not apparent on plain radiographs, and shows that MRI is useful when diagnosing other pathology such as malignancy, which may not be apparent on plain films.
Thermodynamics of trivalent actinides and neodymium in NaCl, MgCl2, and CaCl2 solutions: Solubility, hydrolysis, and ternary Ca-M(III)-OH complexes
Authors: Neck Volker , Altmaier Marcus , Rabung Thomas , Lützenkirchen Johannes , Fanghänel Thomas 
Published: August 2009

Abstract
Known data on the solubility of Am(OH)3(s) and the hydrolysis of Am(III) and Cm(III), additional information from an extensive solubility study with Nd(OH)3(s) in NaCl, MgCl2, and CaCl2 media of various ionic strengths and spectroscopic (time-resolved laser fluorescence spectroscopy, TRLFS) data for Cm(III) in alkaline CaCl2 solutions are used to evaluate a comprehensive set of standard-state equilibrium constants and ion interaction parameters for the specific ion interaction theory (SIT) and Pitzer equations at 25 °C. The thermodynamic model takes into account the analogous solubility and hydrolysis behavior of trivalent actinides and Nd(III) and covers the entire pH range in dilute to concentrated NaCl, MgCl2, and CaCl2 solutions. In alkali chloride/hydroxide solutions, the formation of the tetrahydroxide complex M(OH)4
– requires OH– concentration above 3 mol l–1, whereas in alkaline CaCl2 solutions (at pHc &lt; 12) M(III) complexes with four and six hydroxide ligands are formed. Similar as the recently detected ternary Ca–M(IV)–OH complexes Ca3[Zr(OH)6]4+ and Ca4[Th(OH)8]4+, these complexes are stabilized by the association of Ca2+ ions. The solubility and hydrolysis of Am(III), Cm(III), and Nd(III) in both Ca-free and -containing solutions is consistently described with a model including the ternary Ca–M(III)–OH complexes Ca[M(OH)3]2+, Ca2[M(OH)4]3+, and Ca3[M(OH)6]3+.
Bone marrow changes in adolescent girls with anorexia nervosa
Authors: Ecklund Kirsten , Vajapeyam Sridhar , Feldman Henry A , Buzney Catherine D , Mulkern Robert V , Kleinman Paul K , Rosen Clifford J , Gordon Catherine M 
Published: August 2009

Abstract
Early osteoporosis is common among adolescent girls with anorexia nervosa (AN) and may result from premature conversion of red (RM) to yellow bone marrow. We performed right knee magnetic resonance imaging (MRI) on a 1.0 T extremity scanner in 20 patients and 20 healthy controls, aged 16.2 ± 1.6 years (mean ± SD). Coronal T1-weighted (T1W) images and T1 maps were generated from T1 relaxometry images. Blinded radiologists visually assessed RM in the distal femoral and proximal tibial metaphyses in T1W images using a scale of signal intensity from 0 (homogeneous hyperintensity, no RM) to 4 (all dark, complete RM). Subjects with AN exhibited nearly twofold lower metaphyseal RM scores in both the femur (0.64 versus 1.22, p = .03) and tibia (0.54 versus 0.96, p = .08). In relaxometric measurements of four selected regions (femur and tibia amd epiphysis and metaphysis), subjects with AN showed higher mean epiphyseal but lower metaphyseal T1. The net AN-control difference between epiphysis and metaphysis was 70 ms in the femur (+31 versus −35 ms, p = .02) and of smaller magnitude in the tibia. In relaxometry data from the full width of the femur adjacent to the growth plate, AN subjects showed mean T1 consistently lower than in controls by 30 to 50 ms in virtually every part of the sampling region. These findings suggest that adolescents with AN exhibit premature conversion of hematopoietic to fat cells in the marrow of the peripheral skeleton potentially owing to adipocyte over osteoblast differentiation in the mesenchymal stem cell pool. © 2010 American Society for Bone and Mineral Research
Endosseous implant anchorage is critically dependent on mechanostructural determinants of peri-implant bone trabeculae
Authors: Gabet Yankel , Kohavi David , Voide Romain , Mueller Thomas L , Müller Ralph , Bab Itai 
Published: August 2009

Abstract
Low bone mass is highly prevalent among patients receiving endosseous implants. In turn, the implantation prognosis in low-density skeletal sites is poor. However, little is known about the mechanostructural determinants of implant anchorage. Using metabolic manipulations that lead to low bone density and to its rescue, we show here that anchorage is critically dependent on the peri-implant bone (PIB). Titanium implants were inserted horizontally into the proximal tibial metaphysis of adult rats 6 weeks after orchiectomy (ORX) or sham ORX. Systemic intermittent administration of human parathyroid hormone (1–34) [iahPTH(1–34)] or vehicle commenced immediately thereafter for 6 weeks. The bone-implant apparatus was then subjected to image-guided failure assessment, which assesses biomechanical properties and microstructural deformation concomitantly. Anchorage failure occurred mainly in PIB trabeculae, 0.5 to 1.0 mm away from the implant. Mechanically, the anchorage performed poorly in ORX-induced low-density bone, attributable mainly to decreased trabecular number. iahPTH(1–34) rescued the PIB density and implant mechanical function by augmenting trabecular thickness (Tb.Th). However, implant biomechanical properties in low-density bone were relatively insensitive to implant surface treatment that affected only the osseointegration (%bone-implant contact). These results support a model wherein anchorage failure involves buckling of the weakest trabecular struts followed by sequential failure of the stronger trabeculae. Treatment with iahPTH(1–34) induced thicker struts, which were able to delay and even prevent failure of individual elements, thus implicating trabecular thickness as a prime target for enhancing implant anchorage by systemic bone anabolic therapy. © 2010 American Society for Bone and Mineral Research.
Early smoking is associated with peak bone mass and prevalent fractures in young, healthy men
Authors: Taes Youri , Lapauw Bruno , Vanbillemont Griet , Bogaert Veerle , De Bacquer Dirk , Goemaere Stefan , Zmierczak Hans , Kaufman Jean-Marc 
Published: August 2009

Abstract
Smoking is associated with lower areal bone mineral density (aBMD) and higher fracture risk, although most evidence has been derived from studies in elderly subjects. This study investigates smoking habits in relation to areal and volumetric bone parameters and fracture prevalence in young, healthy males at peak bone mass. Healthy male siblings (n = 677) at the age of peak bone mass (25 to 45 years) were recruited in a cross-sectional population-based study. Trabecular and cortical bone parameters of the radius and cortical bone parameters of the tibia were assessed using peripheral quantitative computed tomography (pQCT). Areal bone mass was determined using dual energy X-ray absorptiometry (DXA). Sex steroids and bone markers were determined using immunoassays. Prevalent fractures and smoking habits were assessed using questionnaires. Self-reported fractures were more prevalent in the current and early smokers than in the never smokers (p &lt; .05), with a fracture prevalence odds ratio for early smokers of 1.96 (95% confidence interval 1.18–3.24) after adjustment for age, weight, educational level, and alcohol use and exclusion of childhood fractures. Current smoking was associated with a larger endosteal circumference (β = 0.027 ± 0.009, p = .016) and a decreased cortical thickness (β = −0.034 ± 0.01, p = .020) at the tibia. In particular, early smokers (≤16 years) had a high fracture risk and lower areal BMD, together with a lower cortical bone area at the tibia and lower trabecular and cortical bone density at the radius. An interaction between free estradiol and current smoking was observed in statistical models predicting cortical area and thickness (β = 0.29 ± 0.11, p = .01). In conclusion, smoking at a young age is associated with unfavorable bone geometry and density and is associated with increased fracture prevalence, providing arguments for a disturbed acquisition of peak bone mass during puberty by smoking, possibly owing to an interaction with sex steroid action. © 2010 American Society for Bone and Mineral Research
Heritability of Risk-Taking in Adolescence: A Longitudinal Twin Study
Authors: Anokhin Andrey P. , Golosheykin Simon , Grant Julia , Heath Andrew C. 
Published: August 2009

AbstractAdolescents are prone to risk-taking behaviors leading to adverse consequences such as substance abuse, accidents, violence, and victimization. However, little is known about the contribution of genetic and environmental factors to individual differences in the propensity for risk-taking. This study investigated developmental changes, longitudinal stability, and heritability of risk-taking using data from 752 adolescent twins including 169 MZ and 203 DZ pairs. The Balloon Analogue Risk Task (BART), an experimental behavioral measure of risk taking, was administered to the twins at age 12 and then re-administered to a part of this sample at age 14. Risk-taking increased with age, but individual differences showed a significant longitudinal stability. Genetic model fitting showed that at age 12, heritability of risk-taking was modest but significant in both sexes, whereas at age 14, heritability increased to 55% in males and became nonsignificant in females. The findings suggest that propensity for risk-taking as measured by BART can be a useful endophenotype for genetic studies of adolescent externalizing psychopathology, however, the utility of this measure may be limited by sex differences in heritability.
Laminar Box System for 1-g Physical Modeling of Liquefaction and Lateral Spreading
Authors: Thevanayagam S. , Kanagalingam T. , Reinhorn A. , Tharmendhira R. , Dobry R. , Pitman M. , Abdoun T. , Elgamal A. , Zeghal M. , Ecemis N. , El Shamy U. 
Published: August 2009

AbstractDetails of a large scale modular 1-g laminar box system capable of simulating seismic induced liquefaction and lateral spreading response of level or gently sloping loose deposits of up to 6 m depth are presented. The internal dimensions of the largest module are 5 m in length and 2.75 m in width. The system includes a two dimensional laminar box made of 24 laminates stacked on top of each other supported by ball bearings, a base shaker resting on a strong floor, two computer controlled high speed actuators mounted on a strong wall, a dense array advanced instrumentation, and a novel system for laboratory hydraulic placement of loose sand deposit, which mimics underwater deposition in a narrow density range. The stacks of laminates slide on each other using a low-friction high-load capacity ball bearing system placed between each laminate. It could also be reconfigured into two smaller modules that are 2.5 m wide, 2.75 m long, and up to 3 m high. The maximum shear strain achievable in this system is 15 %. A limited set of instrumentation data is presented to highlight the capabilities of this equipment system. The reliability of the dense array sensor data is illustrated using cross comparison of accelerations and displacements measured by different types of sensors.